Perspectives for the chemotherapy of respiratory syncytial virus (RSV) infections

International Journal of Antimicrobial Agents

Volumn 7, Issue 3, 1996, Pages 193-202

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Aerosol; Antiviral drugs; Cyclopentenylcytosine; EICAR; Polyanions; Pyrazofurin; Respiratory syncytial virus (RSV); Ribavirin

Indexed keywords

1 (4,5 DIHYDROXY 3 HYDROXYMETHYL 2 CYCLOPENTEN 1 YL)CYTOSINE; ANTIVIRUS AGENT; DEXTRAN SULFATE; HEPARIN; INOSINATE DEHYDROGENASE INHIBITOR; PIRAZOFURIN; POLYANION; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AEROSOL; ANIMAL MODEL; ANTIVIRAL ACTIVITY; CHILD; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; INFANT; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; PHARMACEUTICS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; TOPICAL DRUG ADMINISTRATION; VIRUS REPLICATION;

EID: 0029764365     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(96)00319-6     Document Type: Article

References (63)

1. Carmack MA, Prober CG. Respiratory syncytial virus and ribavirin: quo vadis? Infect Agents Dis 1992;1:99-107.
2. Avery RK, Longworth DL. Viral pulmonary infections in thoracic and cardiovascular surgery. Semin Thorac Cardiovasc Surg 1995;7:88-94.
3. Waner JL. Mixed viral infections: detection and management. Clin Microbiol Rev 1994;7:143-151.
4. Walker TA, Khurana S, Tilden SJ. Viral respiratory infections. Pediatr Clin North Am 1994;41:1365-1381.
5. Makela MJ, Ruuskanen O. Ogra PL. Treatment of respiratory syncytial virus infections in children. Ann Med 1994;26:341-343.
6. Groothuis JR, Woodin KA, Katz R, Robertson AD, McBride JT, Hall CB, McWilliams BC, Lauer BA. Early ribavirin treatment of respiratory syncytial viral infection in high-risk children. J Pediatr 1990;117:792-798.
7. Smith DW, Frankel LR, Mathers LH, Tang AT, Ariagno RL, Prober CG. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med 1991;325:24-29.
8. Englund JA, Piedra PA, Ahn YM, Gilbert BE, Hiatt P. High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection. J Pediatr 1994;125:635-641.
9. Zucker AR, Meadow WL. Pediatric critical care physicians' attitudes about guidelines for the use of ribavirin in critically ill children with respiratory syncytial virus pneumonia. Crit Care Med 1995;23:767-772.
10. Wheeler JG, Wofford J, Turner RB. Historical cohort evaluation of ribavirin efficacy in respiratory syncytial virus infection. Pediatr Infect Dis J 1993;12:209-213.
11. Hebert MF, Guglielmo BJ. What is the clinical role of aerosolized ribavirin? DICP 1990;24:735-738.
12. Witvrouw M, Desmyter J, De Clercq E. Antiviral portrait series: 4. Polysulfates as inhibitors of HIV and other enveloped viruses. Antiviral Chem Chemother 1994;5:345-359.
13. Hosoya M, Balzarini J, Shigeta S, De Clercq E. Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retroviruses, depending on the composition of the target amino acid sequences of the viral envelope glycoproteins. Antimicrob Agents Chemother 1991;35:2515-2520.
14. Dubovi EJ, Geratz JD, Tidwell RR. Inhibition of respiratory syncytial virus by bis(5-amidino-2-benzimidazolyl)methane. Virology 1980;103:502-504.
15. Dubovi EJ, Geratz JD, Shaver SR, Tidwell RR. Inhibition of respiratory syncytial virus-host cell interactions by mono- and diamidines. Antimicrob Agents Chemother 1981;19:649-656.
16. Shigeta S, Mori S, Baba M et al. Inhibitory effect of pyridobenzoazoles on orthomyxo- and paramyxovirus replication in vitro. Antiviral Chem Chemother 1992;3:171-177.
17. Balzarini J, Karlsson A, Wang L et al. EICAR (5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide). A novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis. J Biol Chem 1993;268:24591-24598.
18. De Clercq E. 5-Adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents. Biochem Pharmacol 1987;36:2567-2575.
19. De Clercq E. Antiviral activity spectrum and target of action of different classes of nucleoside analogues. Nucleosides Nucleotides 1994;13:1271-1295.
20. Kawana F, Shigeta S, Hosoya M, Suzuki H, De Clercq E. Inhibitory effects of antiviral compounds on respiratory syncytial virus replication in vitro. Antimicrob Agents Chemother 1987;31:1225-1230.
21. Chen X, Schneller SW, Ikeda S et al. Synthesis and antiviral activity of 5′-deoxypyrazofurin. J Med Chem 1993;36:3727-3730.
22. Huang RC, Panin M, Romito RR, Huang YT. Inhibition of replication of human respiratory syncytial virus by 6-diazo-5-oxo-L-norleucine. Antiviral Res 1994;25:269-279.
23. Woods JM, Marr CLP, Penn CR. Inhibition of respiratory syncytial virus replication in vitro by a pyrazole dicarboxamide analogue of ribavirin. Antiviral Chem Chemother 1994;5:340-343.
24. Todoulou OG, Papadaki-Valiraki AE, Filippatos EC, Ikeda S, De Clercq E. Synthesis and anti-myxovirus activity of some novel N,N′-disubstituted thioureas. Eur J Med Chem 1994;29:127-131.
25. Fytas G, Marakos P, Kolocouris N et al. 3-Cyclopentyl-1-adamantanamines and adamantanemethanamines. Antiviral activity evaluation and convulsions studies. II Farmaco 1994;49:641-647.
26. Kolocouris N, Foscolos GB, Kolocouris A et al. Synthesis and antiviral activity evaluation of some aminoadamantane derivatives. J Med Chem 1994;37:2896-2902.
27. De Clercq E. Cools M, Balzarini J et al. Antiviral activities of 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide and related compounds. Antimicrob Agents Chemother 1991;35:679-684.
28. Shigeta S, Mori S, Baba M et al. Antiviral activities of ribavirin, 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide, and 6′-(R)-6′-C-methylneplanocin A against several ortho- and paramyxoviruses. Antimicrob Agents Chemother 1992;36:435-439.
29. Witvrouw M, Schols D, Andrei G et al. Antiviral activity of low-MM dextran sulphate (derived from dextran MW 1000) compared to dextran sulphate samples of higher MW. Antiviral Chem Chemother 1991;2:171-179.
30. Witvrouw M. Este JA. Mateu MQ et al. Activity of a sulfated polysaccharide extracted from the red seaweed Aghardhiella tenera against human immunodeficiency virus and other enveloped viruses. Antiviral Chem Chemother 1994;5:297-303.
31. Damonte E, Neyts J, Pujol CA et al. Antiviral activity of a sulphated polysaccharide from the red seaweed Nothogenia fastigiata. Biochem Pharmacol 1994;47:2187-2192.
32. Witvrouw M. Schols D, Andrei G et al. New polyacetal polysulphate active against human immunodeficiency virus and other enveloped viruses. Antiviral Chem Chemother 1992;3:351-360.
33. Ikeda S, Neyts J, Verma S, Wickramasinghe A, Mohan P, De Clercq E. In vitro and in vivo inhibition of ortho- and paramyxovirus infections by a new class of sulfonic acid polymers interacting with virus-cell binding and/or fusion. Antimicrob Agents Chemother 1994;38:256-259.
34. Ikeda S, Wong MF, Mohan P, De Clercq E. Selective inhibition of myxovirus replication by a novel series of cholesterol-naphthalenesulfonic acid hybrid molecules. Antiviral Chem Chemother 1994;5:122-127.
35. Neyts J. Reymen D, Letourneur D et al. Differential antiviral activity of derivatized dextrans. Biochem Pharmacol 1995;50:743-751.
36. Yamamoto N, Schols D. De Clercq E et al. Mechanism of anti-human immunodeficiency virus action of polyoxometalates, a class of broad-spectrum antiviral agents. Mol Pharmacol 1992;42:1109-1117.
37. Ikeda S, Neyts J, Yamamoto N et al. In vitro activity of a novel series of polyoxosilicotungstates against human myxo-, herpesand retroviruses. Antiviral Chem Chemother 1993;4:253-262.
38. Hosoya M, Neyts J, Yamamoto N et al. Inhibitory effects of polycations on the replication of enveloped viruses (HIV, HSV, CMV, RSV, influenza A virus and togaviruses) in vitro. Antiviral Chem Chemother 1991;2:243-248.
39. Gabrielsen B, Phelan MJ, Barthel-Rosa L et al. Synthesis and antiviral evaluation of N-carboxamidine-substituted analogues of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride. J Med Chem 1992;35:3231-3238.
40. Shuto S, Obara T, Toriya M et al. New neplanocin analogues. 1. Synthesis of 6′-modified neplanocin A derivatives as broad-spectrum antiviral agents. J Med Chem 1992;35:324-331.
41. De Clercq E, Murase J, Marquez VE. Broad-spectrum antiviral and cytocidal activity of cyclopentenylcytosine, a carbocyclic nucleoside targeted at CTP synthetase. Biochem Pharmacol 1991;41:1821-1829.
42. De Clercq E, Bernaerts R, Shealy YF, Montgomery JA. Broad-spectrum antiviral activity of carbodine. the carbocyclic analogue of cytidine. Biochem Pharmacol 1990;39:319-325.
43. Patil SD, Schneller SW, Hosoya M et al. Synthesis and antiviral properties of (±)-5′-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design. J Med Chem 1992;35:3372-3377.
44. Siddiqi SM, Chen X, Schneller SW et al. Antiviral enantiomeric preference for 5′-noraristeromycin. J Med Chem 1994;37:551-554.
45. Siddiqi SM, Chen X, Schneller SW et al. An epimer of 5′-noraristeromycin and its antiviral properties. J Med Chem 1994;37:1382-1384.
46. Siddiqi SM, Chen X, Rao J et al. 3-Deaza- and 7-deaza-5′-noraristeromycin and their antiviral properties. J Med Chem 1995;38:1035-1038.
47. Schols D, De Clercq E, Balzarini J et al. Sulphated polymers are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, respiratory syncytial virus, and toga-, arena- and retroviruses. Antiviral Chem Chemother 1990;1:233-240.
48. Descamps J, De Clercq E. Broad-spectrum antiviral activity of pyrazofurin (pyrazomycin). In: Current Chemotherapy. American Society for Microbiology, 1978, pp. 354-357.
49. Mohan P, Schols D, Baba M. De Clercq E. Sulfonic acid polymers as a new class of human immunodeficiency virus inhibitors. Antiviral Res 1992;18:139-150.
50. Andrei G, De Clercq E. Inhibitory effect of selected antiviral compounds on arenavirus replication in vitro. Antiviral Res 1990;14:287-300.
51. Shigeta S, Konno K, Yokota T, Nakamura K, De Clercq E. Comparative activities of several nucleoside analogs against influenza A, B and C viruses in vitro. Antimicrob Agents Chemother 1988;32:906-911.
52. Hruska JF, Morrow PE. Suffln SC, Douglas Jr RG. In vivo inhibition of respiratory syncytial virus by ribavirin. Antimicrob Agents Chemother 1982;21:125-130.
53. Tidwell RR. Geratz JD. Clyde Jr WA, Rosenthal KU, Dubovi EJ. Suppression of respiratory syncytial virus infection in cotton rats by bis(5-amidino-2-benzimidazolyl)methane. Antimicrob Agents Chemother 1984;26:591-593.
54. Wyde PR, Wilson SZ, Petrella R, Gilbert BE. Efficacy of high dose-short duration ribavirin aerosol in the treatment of respiratory syncytial virus infected cotton rats and influenza B virus infected mice. Antiviral Res 1987;7:211-220.
55. Wyde PR. Ambrose MW, Meyer HL, Zolinski CL, Gilbert BE. Evaluation of the toxicity and antiviral activity of carbocyclic 3-deazaadenosine against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats. Antiviral Res 1990;14:214-226.
56. Gilbert BE, Wyde PR, Wilson SZ, Meyerson LR. SP-303 small-particle aerosol treatment of influenza A virus infection in mice and respiratory syncytial virus infection in cotton rats. Antiviral Res 1993;21:37-45.
57. Gilbert BE, Wyde PR, Ambrose MW, Wilson SZ, Knight V. Further studies with short duration ribavirin aerosol for the treatment of influenza virus infection in mice and respiratory syncytial virus infection in cotton rats. Antiviral Res 1992;17:33-42.
58. Taylor G, Stott EJ, Hughes M, Collins AP. Respiratory syncytial virus infection in mice. Infect Immun 1984;43:649-655.
59. Weltzin R, Hsu SA, Mittler ES. Georgakopoulos K, Monath TP. Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice. Antimicrob Agents Chemother 1994;38:2785-2791.
60. Wyde PR, Sun C-S, Knight V. Replication of respiratory syncytial virus in lungs of immunodeficient mice. J Reticuloendothelial Soc 1983;34:125-129.
61. De Clercq E. HIV resistance to reverse transcriptase inhibitors. Biochem Pharmacol 1994;47:155-169.
62. De Clercq E. Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J Med Chem 1995;38:2491-2517.
63. Hruska JF, Bernstein JM, Douglas Jr RG, Hall CB. Effects of ribavirin on respiratory syncytial virus in vitro. Antimicrob Agents Chemother 1980;17:770-775.